← Every applicant
Teva Pharms USA Inc FDA Approvals
25 new drug approvals and 0 device clearances on file. This applicant is not matched to a listed company.
Newest first
A new drug approval is an original application; a 510(k) is a device shown equivalent to one already sold.
| Product |
|---|
| SUGAMMADEX SODIUMNew drugJul 28, 2026SOLUTION, INTRAVENOUS |
| MACITENTANNew drugJun 8, 2026TABLET, ORAL |
| BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATENew drugApr 23, 2026AEROSOL, METERED, INHALATION |
| DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDENew drugApr 6, 2026TABLET, EXTENDED RELEASE, ORAL |
| ESTRADIOLNew drugDec 8, 2025INSERT, VAGINAL |
| PERAMPANELNew drugMay 23, 2025TABLET, ORAL |
| AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATENew drugApr 8, 2025SPRAY, METERED, NASAL |
| LAPATINIB DITOSYLATENew drugAug 16, 2024TABLET, ORAL |
| CYCLOSPORINENew drugDec 14, 2023EMULSION, OPHTHALMIC |
| OCTREOTIDE ACETATENew drugDec 5, 2023INJECTABLE, INJECTION |
| RISPERIDONENew drugDec 5, 2023POWDER, INTRAMUSCULAR |
| PLERIXAFORNew drugJul 24, 2023SOLUTION, SUBCUTANEOUS |
| NALTREXONENew drugJul 6, 2023FOR SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR |
| TASIMELTEONNew drugDec 12, 2022CAPSULE, ORAL |
| APREMILASTNew drugAug 18, 2022TABLET, ORAL |
| BREXPIPRAZOLENew drugAug 11, 2022TABLET, ORAL |
| SOFOSBUVIRNew drugJan 27, 2022TABLET, ORAL |
| LUBIPROSTONENew drugJan 18, 2022CAPSULE, ORAL |
| ELIGLUSTAT TARTRATENew drugDec 27, 2021CAPSULE, ORAL |
| MICAFUNGINNew drugJul 30, 2021POWDER, INTRAVENOUS |
| FORMOTEROL FUMARATENew drugJun 22, 2021SOLUTION, INHALATION |
| TIOPRONINNew drugApr 26, 2021TABLET, ORAL |
| DROXIDOPANew drugFeb 18, 2021CAPSULE, ORAL |
| ERYTHROMYCINNew drugFeb 11, 2021TABLET, ORAL |
| ETHINYL ESTRADIOL; ETONOGESTRELNew drugJan 13, 2021RING, VAGINAL |